Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer

Background Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified and data on post-immunotherapy progression are lacking. We explored the combination of a checkpoint inhibitor (nivolumab) and...

Full description

Bibliographic Details
Main Authors: John Wright, Stephanie Lheureux, Ilaria Colombo, Ramy Gadalla, Pamela S Ohashi, Xuan Li, Lisa Wang, Matthew S Block, David G Brooks, Andrea Jewell, Carolyn McCourt, Eugenia Girda, Sarah Temkin, Gini F Fleming, Linda Duska, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Stephanie L Gaillard, Michael McHale, Floor J Backes, Theresa L Werner, Siobhan Kehoe, Rachel Wildman, Shirin Soleimani, Scott Lien, Trevor Pugh
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e004233.full

Internet

https://jitc.bmj.com/content/10/3/e004233.full

Similar Items